Business
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference
- Patient fecal samples were evaluated for C. difficile culture and microbiome changes - Ph2a trial demonstrated 100% clinical cure and 100% sustained
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"- Patient fecal samples were evaluated for C. difficile culture and microbiome changes\n - Ph2a trial demonstrated 100% clinical cure and 100% sustained clinical cure\n - Favorable microbiome changes included overgrowth of Actinobacteria and Firmicutes phylum species while on therapy\n - New findings demonstrate potentially beneficial effects on bile acid metabolism\n - Clinical results support the expectation that microbiome effects may be predictive of beneficial patient outcomes including low rates of recurrence\n -Phase 2b trial comparing ibezapolstat to vancomycin in CDI patients to begin this month\n\n\nSTATEN ISLAND, N.Y., Nov. 8, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial for C. difficile Infection (CDI) were presented at the 9th International C. diff Conference & Health Expo entitled: \"Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect?\" The presentation was made on November 5, 2021, by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy and the Principal Investigator for microbiome aspects of the ibezapolstat clinical trial program.\nPhase 2a data demonstrated complete eradication of colonic C. difficile by day three of treatment with ibezapolstat as well as the observed overgrowth of healthy gut microbiota, Actinobacteria and Firmicute phyla species, during and after therapy. Very importantly, emerging data show an increased concentration of secondary bile acids during and following ibezapolstat therapy which is known to correlate with colonization resistance against C. difficile. Additionally, a decrease in primary bile acids and the favorable increase in the ratio of secondary-to-primary bile acids suggest that ibezapolstat may reduce the likelihood of CDI recurrence when compared to vancomycin.\nDr. Garey's Presentation can be viewed on the company's website at www.acurxpharma.com, Tab: News Media, Presentations.\nAccording to Dr. Garey, \"The totality of pre-clinical and clinical data-to-date demonstrate that ibezapolstat fulfills the three key criteria for an ideal anti-CDI antibiotic: Ibezapolstat achieves high ...